Drop the Case

[...]a single medicine had many secondary patent applications pending in the Indian patent office covering one or more specific features, including "formulation" (e g, heat stable tablets and capsules, syrups, etc), combinations (e g, a fixed-dose combination when different HIV medicines are combined in the same pill), and derivatives (salts, prodrugs, crystals and polymorphs). [...]it is crucial that developing countries, in particular, make a careful decision in what should be allowed a patent and what should not. 1&f=G&l= 50 & s1= 47 24 32.PN. &OS=PN/ 4724232 & RS= PN/ 4724232 5 ZA9709726, Glaxo Wellcome, 1997, viewed on 30 June 2013, http://apps.who.int/medicinedocs/en/d/Js4913e/7.html 6 Under the 1970 Patents Act, India did not grant product patents on medicines. 7 On 19 November 2003, the South African ;National Department of Health announced an "Operational Plan" for the rollout of ARV medicines in the public health system. Love, James (2013): "R&D Costs for Gleevec", Knowledge Ecology International, 3 April, viewed on 30 June 2013, http://lists.keionline.org/pipermail/ip-health_lists.keionline.org/ 2013-April/003005.html Novartis (2013): "Supreme Court Denial of Glivec Patent Clarifies Limited Intellectual Property Protection and Discourages Future Innovation in India", 1 April, viewed on 30 June 2013, http://www.novartis.com/newsroom/media-releases/1689290.shtml Menghaney, L (2013): "R&D: